{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T09:22:07Z","timestamp":1768987327639,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.contraception.2011.10.003","type":"journal-article","created":{"date-parts":[[2011,12,15]],"date-time":"2011-12-15T13:19:16Z","timestamp":1323955156000},"page":"480-488","source":"Crossref","is-referenced-by-count":48,"title":["Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women"],"prefix":"10.1016","volume":"85","author":[{"given":"Vivian","family":"Brache","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regine","family":"Sitruk-Ware","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alistair","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Blithe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horacio","family":"Croxatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narender","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushma","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Yen","family":"Tsong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irving","family":"Sivin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Nath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Cochon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anibal","family":"Faundes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Daniel","family":"Mishell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2011.10.003_bb0005","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/S0140-6736(06)69480-4","article-title":"Family planning: the unfinished agenda","volume":"18","author":"Cleland","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.10.003_bb0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev.pa.36.040196.000403","article-title":"Antiprogestins: mechanism of action and contraceptive potential","volume":"36","author":"Spitz","year":"1996","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.contraception.2011.10.003_bb0015","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/humrep\/13.4.793","article-title":"Effects of long-term low-dose mifepristone on reproductive function in women","volume":"13","author":"Croxatto","year":"1998","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2011.10.003_bb0020","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/humupd\/dmi002","article-title":"Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications","volume":"11","author":"Chabbert-Buffet","year":"2005","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.contraception.2011.10.003_bb0025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/s-2005-864035","article-title":"Progesterone receptor antagonists and the endometrial antiproliferative effect","volume":"23","author":"Brenner","year":"2005","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.contraception.2011.10.003_bb0030","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0039-128X(00)00190-2","article-title":"Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium","volume":"65","author":"Chwalisz","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2011.10.003_bb0035","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/me.2006-0093","article-title":"A novel pathway involving progesterone receptor, endothelin-2, and endothelin receptor B controls ovulation in mice","volume":"20","author":"Palanisamy","year":"2006","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.contraception.2011.10.003_bb0040","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/humrep\/deq157","article-title":"Immediate pre-ovulatory administration of 30 mg. ulipristal acetate significantly delays follicular rupture","volume":"25","author":"Brache","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2011.10.003_bb0045","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/humrep\/deh738","article-title":"The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women","volume":"20","author":"Chwalisz","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2011.10.003_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1210\/jc.87.1.63","article-title":"Daily dose mifepristone has contraceptive potential suppressing ovulation and menstruation; a double-blind randomized control trial of 2 and 5 mg per day for 120 days","volume":"87","author":"Brown","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2011.10.003_bb0055","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0039-128X(03)00118-1","article-title":"Development of the selective progesterone receptor modulator CDB-2914 for clinical indications","volume":"68","author":"Blithe","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2011.10.003_bb0060","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/humrep\/15.5.1100","article-title":"Circulating concentrations of antiprogestins CDB-2914 and mifepristone in female rhesus monkey following various routes of administration","volume":"15","author":"Larner","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2011.10.003_bb0065","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0024-3205(93)90135-P","article-title":"Reversal of activity profile in analogs of the antiprogestin RU 486: effect of a 16\u03b1-substituent on progestational (agonist) activity","volume":"52","author":"Cook","year":"1992","journal-title":"Life Sci"},{"key":"10.1016\/j.contraception.2011.10.003_bb0070","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/humrep\/15.4.822","article-title":"CDB-2914: anti-progestational\/anti-glucocorticoid profile and post coital antifertility activity in rats and rabbits","volume":"15","author":"Hild","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2011.10.003_bb0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0303-7207(01)00743-2","article-title":"CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914","volume":"188","author":"Attardi","year":"2002","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.contraception.2011.10.003_bb0080","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jsbmb.2003.12.004","article-title":"In vitro antiprogestational\/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone","volume":"88","author":"Attardi","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.contraception.2011.10.003_bb0085","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/humrep\/15.5.1092","article-title":"A single mid-follicular dose of CDB2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women","volume":"15","author":"Stratton","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2011.10.003_bb0090","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(10)60101-8","article-title":"Ulipristal acetate versus levonorgestrel for emergency contraception: a randomized non-inferiority trial and meta-analysis","volume":"375","author":"Glasier","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.10.003_bb0095","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/AOG.0b013e3181c8e2aa","article-title":"Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception","volume":"115","author":"Fine","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.10.003_bb0100","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1210\/jc.2006-2816","article-title":"Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic\u2013pituitary\u2013ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial","volume":"92","author":"Chabbert-Buffet","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2011.10.003_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0010-7824(02)00474-2","article-title":"Amenorrhea associated with contraception an international study on acceptability","volume":"67","author":"Glasier","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.10.003_bb0110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0010-7824(92)90101-X","article-title":"Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control, and lipid profiles","volume":"46","author":"Alvarez-Sanchez","year":"1992","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.10.003_bb0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.contraception.2004.12.015","article-title":"Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen","volume":"72","author":"Fraser","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.10.003_bb0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003088-200039030-00005","article-title":"Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring","volume":"39","author":"Timmer","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.contraception.2011.10.003_bb0125","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.contraception.2010.04.012","article-title":"Contraceptive vaginal rings: a review","volume":"82","author":"Brache","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.10.003_bb0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.contraception.2010.07.008","article-title":"Vaginal ring contraception","volume":"83","author":"Kerns","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.10.003_bb0135","series-title":"A study to evaluate the effect of a contraceptive vaginal ring delivering a daily dose of 400-500 \u03bcg of CDB-2914 on pharmacokinetics and pharmacodynamics in normal cycling women. Summary study report. Protocol 312","author":"Croxatto","year":"2003"},{"key":"10.1016\/j.contraception.2011.10.003_bb0140","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.steroids.2003.08.012","article-title":"Limitations of direct estradiol and testosterone immunoassay kits","volume":"68","author":"Stanczyk","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2011.10.003_bb0145","series-title":"Blaustein's pathology of the female genital tract","first-page":"383","year":"2002"},{"key":"10.1016\/j.contraception.2011.10.003_bb0150","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptor modulators","volume":"21","author":"Mutter","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.contraception.2011.10.003_bb0155","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0010-7824(98)00067-5","article-title":"Antiovulatory and postcoital antifertility activity of the antiprogestin CDB-2914 when administered as single, multiple, or continuous doses to rats","volume":"58","author":"Reel","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.10.003_bb0160","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/humupd\/dmm023","article-title":"Progesterone receptor modulators and the endometrium: changes and consequences","volume":"13","author":"Horne","year":"2007","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.contraception.2011.10.003_bb0165","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.contraception.2011.10.003_bb0170","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ijc.20710","article-title":"Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort","volume":"114","author":"Fournier","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.contraception.2011.10.003_bb0175","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/humrep\/dem177","article-title":"A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)","volume":"22","author":"Lakha","year":"2007","journal-title":"Hum Reprod"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411005762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411005762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T19:50:49Z","timestamp":1543348249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782411005762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0010782411005762"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2011.10.003","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}